Lab Information
Chen Liang (PhD)
Associate InvestigatorCentre for Translational Biology
Department of Medicine (McGill)
Research Profile
Keywords
HIV • COVID-19 • SARS-CoV • innate immunity • interferon • antiviralsResearch Interests
My research aims to understand the host innate immune responses to viral infections. My team uses the findings to understand viral pathogenesis and transmission and to guide the development of effective antiviral therapeutics. Specifically, we investigate how host cells produce antiviral interferons in response to infections by HIV or SARS-CoV-2, and how these two highly pathogenic viruses overcome and evade this first line of host defense. We are dedicated to the discovery of new HIV treatments and the compounds that can effectively inhibit SARS-CoV-2 and thus cure COVID-19. My lab has also pioneered the application of the CRISPR gene editing tool in curing HIV infection.Team Members
| Name | Position |
|---|
Latest Publications
- Wang, L., Zhou, R., Liu, Y., Guo, S., Yi, D., Zhao, J., Li, Q., Zhang, Y., Liang, C., Wang, J., Shan, G. & Cen, S. (2023). A cell-based assay to discover inhibitors of Zika virus RNA-dependent RNA polymerase. Virology, vol. 589, p. 109939.
- Zhao, F., Hu, Y., Fan, Z., Huang, B., Wei, L., Xie, Y., Huang, Y., Mei, S., Wang, L., Wang, L., Ai, B., Fang, J., Liang, C., Xu, F., Tan, W. & Guo, F. (2023). Rapid and sensitive one-tube detection of mpox virus using RPA-coupled CRISPR-Cas12 assay. Cell reports methods, p. 100620.
- Ding, J., Wang, S., Liu, Q., Duan, Y., Cheng, T., Ye, Z., Cui, Z., Zhang, A., Liu, Q., Zhang, Z., Zhang, N., Liu, Q., An, N., Zhao, J., Yi, D., Li, Q., Wang, J., Zhang, Y., Ma, L., Guo, S., Wang, J., Liang, C., Zhou, J., Cen, S. & Li, X. (2023). Schlafen-5 inhibits LINE-1 retrotransposition. iScience, vol. 26, p. 107968.
- Liu, Q., Yi, D., Ding, J., Mao, Y., Wang, S., Ma, L., Li, Q., Wang, J., Zhang, Y., Zhao, J., Guo, S., Liu, Z., Guo, F., Zhao, D., Liang, C., Li, X., Peng, X. & Cen, S. (2023). MOV10 recruits DCP2 to decap human LINE-1 RNA by forming large cytoplasmic granules with phase separation properties. EMBO reports, p. e56512.
- Wang, Z., Pan, Q., Ma, L., Zhao, J., McIntosh, F., Liu, Z., Ding, S., Lin, R., Chen, S., Finzi, A. & Liang, C. (2023). Anthracyclines inhibit SARS-CoV-2 infection. Virus research, p. 199164.
- Zhao, J., Wang, J., Pang, X., Liu, Z., Li, Q., Yi, D., Zhang, Y., Fang, X., Zhang, T., Zhou, R., Guo, Z., Liu, W., Li, X., Liang, C., Deng, T., Guo, F., Yu, L. & Cen, S. (2023). Author Correction: An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA. Nature communications, vol. 14, p. 3756.
- AbdElFatah, T., Jalali, M., Yedire, S. G., I Hosseini, I., Del Real Mata, C., Khan, H., Hamidi, S. V., Jeanne, O., Siavash Moakhar, R., McLean, M., Patel, D., Wang, Z., McKay, G., Yousefi, M., Nguyen, D., Vidal, S. M., Liang, C. & Mahshid, S. (2023). Nanoplasmonic amplification in microfluidics enables accelerated colorimetric quantification of nucleic acid biomarkers from pathogens. Nature nanotechnology, vol. 18, p. 922-932.
- Arduini, A., Laprise, F. & Liang, C. (2023). SARS-CoV-2 ORF8: A Rapidly Evolving Immune and Viral Modulator in COVID-19. Viruses, vol. 15.
- Solomon, M. & Liang, C. (2023). Pseudotyped Viruses for Retroviruses. Advances in experimental medicine and biology, vol. 1407, p. 61-84.
- Ma, L., Li, Y., Shi, T., Zhu, Z., Zhao, J., Xie, Y., Wen, J., Guo, S., Wang, J., Ding, J., Liang, C., Shan, G., Li, Q., Ge, M. & Cen, S. (2023). Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, vol. 158, p. 114213.
See also
